No Data
No Data
Suzhou Fushilai Pharmaceutical Co., Ltd. (SZSE:301258) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Most readers would already be aware that Suzhou Fushilai Pharmaceutical's (SZSE:301258) stock increased significantly by 38% over the past month. However, we decided to pay attention to the company'
Fujilai (301258.SZ): No plans for cellular immunotherapy
Gelonghui, May 10 | Fujilai (301258.SZ) said on the investor interactive platform that the company has no plans for cellular immunotherapy yet.
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
Fujilai (301258.SZ): R-lipoic acid produced by enzymatic method has been mass-produced and sold abroad
Gelonghui, May 6 | Fujilai (301258.SZ) said on the investor interactive platform that R-lipoic acid produced by the company's enzymatic method has been mass-produced and is currently still in the marketing stage. Whether it can completely replace the original process depends on various factors such as market demand and customer acceptance.
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
Fujilai (301258.SZ): Net profit of 5.786,800 yuan in the first quarter decreased by 88.79% year on year
Gelonghui, April 22 | Fujilai (301258.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 96.2913 million yuan, down 38.47% year on year; net profit attributable to shareholders of listed companies was 5.7868 million yuan, down 88.79% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 3.1951 million yuan, down 92.87% year on year; basic earnings per share were 0.0631 yuan.
No Data